CD33 and acute myeloid leukemia: A humanized antibody specific for a human myelogenous leukemia antigen (CD33) labeled with 213Bi was administered to 18 patients with Acute Myeloid Leukemia and results showed a reduction in circulating blasts in most patients (~80%), whereas no extramedullary toxicity was observed [65].